Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Jürgen Wichmann"'
Autor:
Hans-Georg Wirsching, Manuela Silginer, Elisa Ventura, Will Macnair, Isabel Burghardt, Manfred Claassen, Silvia Gatti, Jürgen Wichmann, Claus Riemer, Hannah Schneider, Michael Weller
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 166-174 (2021)
Glioblastoma is an invariably deadly disease. A subpopulation of glioma stem-like cells (GSCs) drives tumor progression and treatment resistance. Two recent studies demonstrated that neurons form oncogenic glutamatergic electrochemical synapses with
Externí odkaz:
https://doaj.org/article/5adacbaffe714cf49bafa9404a427847
Publikováno v:
CHIMIA, Vol 54, Iss 11 (2000)
A series of cis and trans configured 2,3,4,4a,5,10b-hexahydro-benz[h]isoquinoline-6(1H)-ones 2 were studied with respect to the binding affinity to the 5-HT2 subtype receptors. The influence of substituents in positions 7(R1), 8(R2) and 9(R3) on aff
Externí odkaz:
https://doaj.org/article/bb87abe61208466f8173a3823f08ac4a
Autor:
Joan Seoane, Piergiorgio Pettazzoni, James R. Bischoff, Josep Tabernero, Eva Muñoz-Couselo, Francisco Martínez-Ricarte, Josep González, Abel Ferres-Pijoan, Thomaz E. Topczewski, Esteban Cordero, Marta Cicuendez, Gabriel Schnetzler, Martin Kornacker, Romi Feddersen, Jan Eckmann, Fabian Köchl, Christina Godfried Sie, Marco Berrera, Thomas Lorber, Luca Mangano, Andrea Romagnani, Jasmin Emmenegger, Isabel Cuartas, Alexandra Arias, Jürgen Wichmann, Cornelia Handl, Raffaella Iurlaro, Ester Bonfill-Teixidor
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212aa6ba78627243358b6b35b8752050
https://doi.org/10.1158/0008-5472.22431899.v1
https://doi.org/10.1158/0008-5472.22431899.v1
Autor:
Joan Seoane, Piergiorgio Pettazzoni, James R. Bischoff, Josep Tabernero, Eva Muñoz-Couselo, Francisco Martínez-Ricarte, Josep González, Abel Ferres-Pijoan, Thomaz E. Topczewski, Esteban Cordero, Marta Cicuendez, Gabriel Schnetzler, Martin Kornacker, Romi Feddersen, Jan Eckmann, Fabian Köchl, Christina Godfried Sie, Marco Berrera, Thomas Lorber, Luca Mangano, Andrea Romagnani, Jasmin Emmenegger, Isabel Cuartas, Alexandra Arias, Jürgen Wichmann, Cornelia Handl, Raffaella Iurlaro, Ester Bonfill-Teixidor
The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K–mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b43d2542896eb9c701061b84e09659a
https://doi.org/10.1158/0008-5472.c.6514028.v1
https://doi.org/10.1158/0008-5472.c.6514028.v1
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Purpose:Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi frequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2843c44991336c397978b9069d4f8bb4
https://doi.org/10.1158/1078-0432.c.6531080.v1
https://doi.org/10.1158/1078-0432.c.6531080.v1
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13025a5f335ff95cafd17d5c42454b84
https://doi.org/10.1158/1078-0432.22483133
https://doi.org/10.1158/1078-0432.22483133
Autor:
Piergiorgio Pettazzoni, James R. Bischoff, Bruno Martoglio, Gabriel Schnetzler, Mitchell P. Levesque, Reinhard Dummer, David S. Hewings, Alessandro Brigo, Marina Bacac, Alison Ribeiro, Dominik Rüttinger, Daniela Krummenacher, Daniel Hunziker, Nicolas Frances, Frank Herting, Jan Eckmann, Jasmin Emmenegger, Cornelia Handl, Martin Kornacker, Jeannine Petrig-Schaffland, Thomas Friess, Caroline Rynn, Jürgen Wichmann
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cebd716c1003033988969a2d1ed6815
https://doi.org/10.1158/1078-0432.22483118
https://doi.org/10.1158/1078-0432.22483118
Autor:
Gabriel Schnetzler, Alison Ribeiro, Daniela Krummenacher, Caroline Rynn, Alessandro Brigo, Cornelia Handl, Jasmin Emmenegger, Mitchell P. Levesque, Reinhard Dummer, Nicolas Frances, Daniel Hunziker, Bruno Martoglio, Thomas Friess, Martin Kornacker, Jürgen Wichmann, Dominik Rüttinger, David S. Hewings, Jan Eckmann, Piergiorgio Pettazzoni, Jeannine Petrig-Schaffland, James R. Bischoff, Marina Bacac, Frank Herting
Purpose: Disease progression in BRAF V600E/K positive melanomas to approved BRAF/MEK inhibitor therapies is associated with the development of resistance mediated by RAF dimer inducing mechanisms. Moreover, progressing disease after BRAFi/MEKi freque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221a5401152655dfeb8a4a7630ad3143
https://www.zora.uzh.ch/id/eprint/218288/
https://www.zora.uzh.ch/id/eprint/218288/
Autor:
Ester Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl, Jürgen Wichmann, Alexandra Arias, Isabel Cuartas, Jasmin Emmenegger, Andrea Romagnani, Luca Mangano, Thomas Lorber, Marco Berrera, Christina Godfried Sie, Fabian Köchl, Jan Eckmann, Romi Feddersen, Martin Kornacker, Gabriel Schnetzler, Marta Cicuendez, Esteban Cordero, Thomaz E. Topczewski, Abel Ferres-Pijoan, Josep González, Francisco Martínez-Ricarte, Eva Muñoz-Couselo, Josep Tabernero, James R. Bischoff, Piergiorgio Pettazzoni, Joan Seoane
Publikováno v:
Cancer research. 82(14)
The therapeutic benefit of approved BRAF and MEK inhibitors (BRAFi/MEKi) in patients with brain metastatic BRAF V600E/K–mutated melanoma is limited and transient. Resistance largely occurs through the restoration of MAPK signaling via paradoxical B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c63bc7b88ce75e76e795dc93e8edd8c4
https://pubmed.ncbi.nlm.nih.gov/35584009
https://pubmed.ncbi.nlm.nih.gov/35584009
Autor:
Michael Weller, Silvia Gatti, Will Macnair, Isabel Burghardt, Hannah Schneider, Manfred Claassen, Manuela Silginer, Hans-Georg Wirsching, Claus Riemer, Jürgen Wichmann, Elisa Ventura
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 166-174 (2021)
Molecular Therapy-Oncolytics, 20
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 166-174 (2021)
Molecular Therapy-Oncolytics, 20
Glioblastoma is an invariably deadly disease. A subpopulation of glioma stem-like cells (GSCs) drives tumor progression and treatment resistance. Two recent studies demonstrated that neurons form oncogenic glutamatergic electrochemical synapses with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e59bd89608c424a286535dab48412f07